Co-Diagnostics earnings release, May 14, 2026

Co-Diagnostics, Inc. (CODX) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Co-Diagnostics

Reports First Quarter 2026 Financial Results

Advancing

Global Commercialization Through CoSara Regulatory Progress and Regional Expansion

Executing

Clinical Strategy with Upper Respiratory Submission Preparation and TB Study Initiation

Expanding

International Presence and Reinforcing Platform Differentiation Through Partnerships and IP

Salt

Lake City, UT – May 14, 2026 – Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx,” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the first quarter ended March 31, 2026.

First

Quarter 2026 Business Highlights:

First

Quarter 2026 Financial Results:

“The progress we’ve made across the business is translating into tangible milestones and expanded opportunities,” said Dwight

Egan, Chief Executive Officer of Co-Diagnostics. “During the quarter, we advanced key initiatives across our clinical pipeline, strengthened our presence in strategic global markets through CoSara and CoMira, and continued to build the foundation for a scalable, globally deployable diagnostics platform. These efforts reflect a focused strategy centered on execution, innovation, and expanding our reach into high-need markets.”

Mr.

Egan continued, “We believe we have generated the data needed to support a regulatory submission for our upper respiratory multiplex test and are advancing toward a

510(k) filing with the

FDA.

We are also preparing to initiate clinical performance studies for our

MTB program in India, which we believe represents one of the most significant near-term opportunities for the platform. Together with continued progress across our international initiatives, these developments demonstrate continued operational progress against our strategy and that we are entering the next phase of execution with increasing momentum and a clearer path toward commercialization.”

Recent

Developments:

Conference

Call and Webcast:

Co-Diagnostics will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors.

The conference call and webcast will be available via:

Webcast: ir.co-dx.com on the

Events & Webcasts page, or accessible directly here

Conference

Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)

The call will be recorded and later made available on the Company’s website.

*The

Co-Dx PCR platform (including the PCR

Home

TM, PCR

Pro

TM, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About

Co-Diagnostics, Inc.

Co-Diagnostics,

Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.

The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules

(DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform

(subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Non-GAAP

Financial Measures:

This press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation, amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, change in fair value of contingent consideration, and realized gain (loss) on investments. The Company believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company’s management uses this non-GAAP measure to compare the Company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

Management does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable

GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.

Forward-Looking

Statements:

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Product revenue145,95450,277
Total revenue145,95450,277
Cost of revenue193,76821,590
Gross profit (loss)-47,81428,687
Operating expensesSales and marketing467,955657,030
Operating expensesGeneral and administrative2,503,1262,773,149
Operating expensesResearch and development5,934,0714,870,019
Operating expensesDepreciation and amortization255,445280,445
Operating expensesTotal operating expenses9,160,5978,580,643
Operating expensesLoss from operations-9,208,411-8,551,956
Other income, netInterest income, net6,97413,601
Other income, netRealized gain on investments301,465
Other income, netGain on remeasurement of acquisition contingencies75,280717,067
Other income, netLoss on equity method investment in joint ventures-13,361-1,444
Other income, netTotal other income, net68,8931,030,689
Other income, netLoss before income taxes-9,139,518-7,521,267
Other income, netIncome tax provision52012,004
Other income, netNet loss-9,140,038-7,533,271
Other comprehensive income (loss)Change in net unrealized gains (losses) on marketable securities, net of tax-87,790
Other comprehensive income (loss)Total other comprehensive income (loss)$--87,790
Other comprehensive income (loss)Comprehensive loss-9,140,038-7,621,061
Loss per common share:Basic and Diluted-4.06-7.05
Weighted average shares outstanding:Basic and Diluted2,253,4741,068,299

Balance Sheet

March 31, 2026 — (Unaudited)

March 31, 2026December 31, 2025
Current assetsCash and cash equivalents8,230,98411,884,607
Current assetsAccounts receivable, net82,339190,375
Current assetsInventory, net846,119992,397
Current assetsIncome taxes receivable4944,559
Current assetsPrepaid expenses and other current assets622,760581,527
Current assetsTotal current assets9,782,25113,693,465
Current assetsProperty and equipment, net2,158,6702,272,098
Current assetsOperating lease right-of-use asset2,002,5971,207,453
Current assetsIntangible assets, net7,219,0007,219,000
Current assetsInvestment in joint ventures337,208350,569
Current assetsTotal assets21,499,72624,742,585
Current liabilitiesAccounts payable2,017,8521,878,225
Current liabilitiesAccrued expenses1,364,754865,301
Current liabilitiesOperating lease liability, current857,638662,258
Current liabilitiesContingent consideration liabilities, current43,756119,036
Current liabilitiesDeferred revenue60014,800
Current liabilitiesTotal current liabilities4,284,6003,539,620
Long-term liabilitiesOperating lease liability1,172,716574,301
Long-term liabilitiesTotal long-term liabilities1,172,716574,301
Long-term liabilitiesTotal liabilities5,457,3164,113,921
Stockholders’ equityCommon stock, $0.001 par value; 100,000,000 shares authorized; 3,764,088 shares issued and 3,602,465 shares outstanding as of March 31, 2026 and 2,256,654 shares issued and 2,095,031 shares outstanding as of December 31, 202569,20767,700
Stockholders’ equityTreasury stock, at cost; 161,623 shares held as of March 31, 2026 and December 31, 2025, respectively-15,575,795-15,575,795
Stockholders’ equityAdditional paid-in capital121,062,575116,510,298
Stockholders’ equityAccumulated deficit-89,513,577-80,373,539
Stockholders’ equityTotal stockholders’ equity16,042,41020,628,664
Stockholders’ equityTotal liabilities and stockholders’ equity21,499,72624,742,585
Full release

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,”

“expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include,... (truncated)ry submission, clearance, authorization, and commercialization of the Co-Dx PCR platform and related tests; (ii) anticipated timing and progress of clinical studies and regulatory submissions; (iii) commercialization and manufacturing activities involving CoSara and CoMira; (iv) anticipated market opportunities and international expansion initiatives; (v) the expected capabilities, differentiation, and adoption of the Company’s platform technologies; and (vi) the Company’s strategic, operational, and growth initiatives generally. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements.

There can be no assurance that any regulatory submission, authorization, commercialization milestone, manufacturing initiative, strategic collaboration, or market opportunity will occur on the timelines anticipated by the Company, or at all, due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange

Commission (SEC) on March 31, 2026, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Company

Contact:

Andrew

Benson

Head of Investor Relations

+1

801-438-1036 investors@codiagnostics.com

Investor

Contact:

Valter

Pinto, Managing Director

KCSA

Strategic Communications

+1

212.896.1254

CODX@KCSA.com

Media

Contact:

Jennifer

Webb

ColtrinMethod

PR jcoltrin@coltrinmethodpr.com

CO-DIAGNOSTICS,

INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Co-Diagnostics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.